NICE gives new nods to Effient, Xtandi, Yervoy; Turkish man pleads guilty in Avastin smuggling case;

Lilly

@FiercePharma: Best-read FP story Tuesday: News flash for biopharma bosses: More than half your employees want to leave. Article | Follow @FiercePharma

@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. Story from FierceAnimalHealth | Follow @EricPFierce

Sept. 15-17,2020

Cytiva Virtual Event: Tapas & Tech Talks Copy - Strategies for robust and scalable

Strategies for robust and scalable processes: from research through late-stage trials
(with Cytiva and IQVIA)

@CarlyHFierce: Brand websites drive new patients to scripts--and old patients to refills. FiercePharmaMarketing story | Follow @CarlyHFierce

> U.K. cost-effectiveness watchdogs gave the green light to several Big Pharma drugs, including wider use of Eli Lilly ($LLY) and Daiichi Sankyo's blood thinner Effient; Medivation ($MDVN) and Astellas' prostate cancer treatment Xtandi; and Bristol-Myers Squibb's ($BMY) melanoma drug Yervoy. Release | Report

> A Turkish man pleaded guilty to federal charges of smuggling counterfeit drugs into the U.S., including an unapproved version of Roche's ($RHHBY) cancer treatment Avastin. Report

> Some doctors checking the new Sunshine Act database of pharma payments to physicians have found an error message where their $0 payments figure should be. Report

> GlaxoSmithKline's ($GSK) consumer healthcare sales fell last quarter because of supply interruptions. Report

Medical Device News

@FierceMedDev: 3-D printing grows to scale within industry. Feature | Follow @FierceMedDev

@StacyALawrence: Smart bandage advances patient monitoring technology. Article | Follow @StacyALawrence

@VarunSaxena2: Frieden: stresses importance of stopping hospital-acquired infections. Sepsis, even Ebola, can be picked up at hospital. | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. Story | Follow @MichaelGFierce

@EmilyWFierce: Power morcellator devices increase levels of undetected cancers in women, according to a new study. More | Follow @EmilyWFierce

> Catheters for deep vein thrombosis may do more harm than good. Story

> NeuroPace stimulator to be deployed in $40M DOD brain research initiative. More

> JAMA: Power morcellator devices increase levels of undetected cancers in women. Article

Biotech News

@FierceBiotech: Sofinnova closes $500M venture fund, keeps late-stage focus. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI - Puma shares triple on positive PhIII neratinib data, plans to file for approval. News | Follow @JohnCFierce

@DamianFierce: NIH funding for infectious disease research is on the rise. Brain disorders, not so much. More, via @EmilyMFierce: FierceBiotech Research report | Follow @DamianFierce

@EmilyMFierce: Not good. Sierra Leone's chief Ebola doctor contracts the virus. More from Reuters | Follow @EmilyMFierce

> Eagle Pharma nabs FDA OK for hyperthermia drug. Item

> Shire inks a $225M rare disease deal on the eve of life with AbbVie. More

> UCB inches toward the FDA with its latest epilepsy contender. Article

> Inovio vs. Feuerstein, Round II: Biotech claims PhII success for VGX-3100. More

Drug Delivery News

> Most absorbent material on Earth gives poorly soluble drugs a boost. News

> Titan Phase III trial for subdermal implant begins enrollment. More

> MIT engineers discover key mechanism behind gold nanoparticle delivery. Article

> Galena Biopharma to market anti-vomit oral soluble film to cancer patients. Item

> Phase II trial kicks off for sublingually delivered Parkinson's therapy. Story

Diagnostics News

> AIDS 2014: Norway's Bionor produces possible biomarker to predict HIV vaccine effectiveness. Report

> PA startup's Series B will bring arthroscopic Dx needle through FDA clearance and launch. More

> GeneCentric grabs $5M Series A to advance testing for personalized cancer treatments. Story

> Quest forks over milestone payments to French Dx company in development deal. Article

> A missile, a plane crash and a profound loss to AIDS research. Editor's corner

Pharma Marketing News

> Pop some corks, Tecfidera sales folks: Your $700M for Q2 trounced estimates. More

> Brand websites drive new patients to scripts--and old patients to refills. Story

> Pfizer peddles advice for the lovelorn in Asia contraceptive campaign. Report

> Do teens hear what we hear? FDA aims to find out in study of acne, ADHD ads. Story

> FDA fast-tracks Roche's Avastin for tough-to-treat ovarian cancer. Article

And Finally... Patients are more likely to stop taking their meds if their shape or color changes. Report

Read more on

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.